Human Molecular Genetics, 2000, Vol. 9, No. 15 2251-2261
© 2000 Oxford University Press
Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes
Laboratory for Neurogenetics and 1Neural Architecture Laboratory, Brain Science Institute and 2Antibiotics Laboratory, The Institute of Physical and Chemical Research (RIKEN), 21 Hirosawa, Wako-shi, Saitama 351-0198, Japan and 3Epilepsy Genomics Laboratories, Comprehensive Epilepsy Program, UCLA School of Medicine and VA GLAHS West Los Angeles Medical Center, Los Angeles, CA, USA
The progressive myoclonus epilepsy of Lafora type is an autosomal recessive disorder caused by mutations in the EPM2A gene. EPM2A is predicted to encode a putative tyrosine phosphatase protein, named laforin, whose full sequence has not yet been reported. In order to understand the function of the EPM2A gene, we isolated a full-length cDNA, raised an antibody and characterized its protein product. The full-length clone predicts a 38 kDa laforin that was very close to the size detected in transfected cells. Recombinant laforin was able to hydrolyze phosphotyrosine as well as phosphoserine/threonine substrates, demonstrating that laforin is an active dual-specificity phosphatase. Biochemical, immunofluorescence and electron microscopic studies on the full-length laforin expressed in HeLa cells revealed that laforin is a cytoplasmic protein associated with polyribosomes, possibly through a conformation-dependent proteinprotein interaction. We analyzed the intracellular targeting of two laforin mutants with missense mutations. Expression of both mutants resulted in ubiquitin-positive perinuclear aggregates suggesting that they were misfolded proteins targeted for degradation. Our results suggest that laforin is involved in translational regulation and that protein misfolding may be one of the molecular bases of the Lafora disease phenotype caused by missense mutations in the EPM2A gene.
+ To whom correspondence should be addressed. Tel: +81 48 467 9703; Fax: +81 48 462 4796; Email: yamakawa@brain.riken.go.jp
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
R. Puri, T. Suzuki, K. Yamakawa, and S. Ganesh Hyperphosphorylation and Aggregation of Tau in Laforin-deficient Mice, an Animal Model for Lafora Disease J. Biol. Chem., August 21, 2009; 284(34): 22657 - 22663. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Liu, Y. Wang, C. Wu, Y. Liu, and P. Zheng Deletions and missense mutations of EPM2A exacerbate unfolded protein response and apoptosis of neuronal cells induced by endoplasm reticulum stress Hum. Mol. Genet., July 15, 2009; 18(14): 2622 - 2631. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Garyali, P. Siwach, P. K. Singh, R. Puri, S. Mittal, S. Sengupta, R. Parihar, and S. Ganesh The malin-laforin complex suppresses the cellular toxicity of misfolded proteins by promoting their degradation through the ubiquitin-proteasome system Hum. Mol. Genet., February 15, 2009; 18(4): 688 - 700. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Liu, L. Wang, C. Chen, Y. Liu, P. Zhou, Y. Wang, X. Wang, J. Turnbull, B. A. Minassian, Y. Liu, et al. Laforin Negatively Regulates Cell Cycle Progression through Glycogen Synthase Kinase 3{beta}-Dependent Mechanisms Mol. Cell. Biol., December 1, 2008; 28(23): 7236 - 7244. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Dubey and S. Ganesh Modulation of functional properties of laforin phosphatase by alternative splicing reveals a novel mechanism for the EPM2A gene in Lafora progressive myoclonus epilepsy Hum. Mol. Genet., October 1, 2008; 17(19): 3010 - 3020. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Cheng, M. Zhang, M. S. Gentry, C. A. Worby, J. E. Dixon, and A. R. Saltiel A role for AGL ubiquitination in the glycogen storage disorders of Lafora and Cori's disease Genes & Dev., October 1, 2007; 21(19): 2399 - 2409. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Gentry, R. H. Dowen III, C. A. Worby, S. Mattoo, J. R. Ecker, and J. E. Dixon The phosphatase laforin crosses evolutionary boundaries and links carbohydrate metabolism to neuronal disease J. Cell Biol., July 24, 2007; 178(3): 477 - 488. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mittal, D. Dubey, K. Yamakawa, and S. Ganesh Lafora disease proteins malin and laforin are recruited to aggresomes in response to proteasomal impairment Hum. Mol. Genet., April 1, 2007; 16(7): 753 - 762. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Lohi, J. Turnbull, X. C. Zhao, S. Pullenayegum, L. Ianzano, M. Yahyaoui, M. A. Mikati, N. P. Quinn, S. Franceschetti, F. Zara, et al. Genetic diagnosis in Lafora disease: Genotype-phenotype correlations and diagnostic pitfalls Neurology, March 27, 2007; 68(13): 996 - 1001. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Liu, Y. Wang, C. Wu, Y. Liu, and P. Zheng Dimerization of Laforin Is Required for Its Optimal Phosphatase Activity, Regulation of GSK3beta Phosphorylation, and Wnt Signaling J. Biol. Chem., November 17, 2006; 281(46): 34768 - 34774. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Worby, M. S. Gentry, and J. E. Dixon Laforin, a Dual Specificity Phosphatase That Dephosphorylates Complex Carbohydrates J. Biol. Chem., October 13, 2006; 281(41): 30412 - 30418. [Abstract] [Full Text] [PDF] |
||||
![]() |
S Singh, I Sethi, S Francheschetti, C Riggio, G Avanzini, K Yamakawa, A V Delgado-Escueta, and S Ganesh Novel NHLRC1 mutations and genotype-phenotype correlations in patients with Lafora's progressive myoclonic epilepsy. J. Med. Genet., September 1, 2006; 43(9): e48 - e48. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Lohi, L. Ianzano, X.-C. Zhao, E. M. Chan, J. Turnbull, S. W. Scherer, C. A. Ackerley, and B. A. Minassian Novel glycogen synthase kinase 3 and ubiquitination pathways in progressive myoclonus epilepsy Hum. Mol. Genet., September 15, 2005; 14(18): 2727 - 2736. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Gentry, C. A. Worby, and J. E. Dixon From The Cover: Insights into Lafora disease: Malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin PNAS, June 14, 2005; 102(24): 8501 - 8506. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Chan, C. A. Ackerley, H. Lohi, L. Ianzano, M. A. Cortez, P. Shannon, S. W. Scherer, and B. A. Minassian Laforin preferentially binds the neurotoxic starch-like polyglucosans, which form in its absence in progressive myoclonus epilepsy Hum. Mol. Genet., June 1, 2004; 13(11): 1117 - 1129. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Fernandez-Sanchez, O. Criado-Garcia, K. E. Heath, B. Garcia-Fojeda, I. Medrano-Fernandez, P. Gomez-Garre, P. Sanz, J. M. Serratosa, and S. Rodriguez de Cordoba Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation Hum. Mol. Genet., December 1, 2003; 12(23): 3161 - 3171. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ganesh, N. Tsurutani, T. Suzuki, K. Ueda, K. L. Agarwala, H. Osada, A. V. Delgado-Escueta, and K. Yamakawa The Lafora disease gene product laforin interacts with HIRIP5, a phylogenetically conserved protein containing a NifU-like domain Hum. Mol. Genet., September 15, 2003; 12(18): 2359 - 2368. [Abstract] [Full Text] [PDF] |
||||
![]() |
E M Chan, D E Bulman, A D Paterson, J Turnbull, E Andermann, F Andermann, G A Rouleau, A V Delgado-Escueta, S W Scherer, and B A Minassian Genetic mapping of a new Lafora progressive myoclonus epilepsy locus (EPM2B) on 6p22 J. Med. Genet., September 1, 2003; 40(9): 671 - 675. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Taylor, I. E. Scheffer, and S. F. Berkovic Occipital epilepsies: identification of specific and newly recognized syndromes Brain, April 1, 2003; 126(4): 753 - 769. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Di Giaimo, M. Riccio, S. Santi, C. Galeotti, D. C. Ambrosetti, and M. Melli New insights into the molecular basis of progressive myoclonus epilepsy: a multiprotein complex with cystatin B Hum. Mol. Genet., November 1, 2002; 11(23): 2941 - 2950. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ganesh, A. V. Delgado-Escueta, T. Sakamoto, M. R. Avila, J. Machado-Salas, Y. Hoshii, T. Akagi, H. Gomi, T. Suzuki, K. Amano, et al. Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice Hum. Mol. Genet., May 16, 2002; 11(11): 1251 - 1262. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ganesh, A. V. Delgado-Escueta, T. Suzuki, S. Francheschetti, C. Riggio, G. Avanzini, A. Rabinowicz, S. Bohlega, J. Bailey, M. E. Alonso, et al. Genotype-phenotype correlations for EPM2A mutations in Lafora's progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype Hum. Mol. Genet., May 16, 2002; 11(11): 1263 - 1271. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Wang, J. A. Stuckey, M. J. Wishart, and J. E. Dixon A Unique Carbohydrate Binding Domain Targets the Lafora Disease Phosphatase to Glycogen J. Biol. Chem., January 18, 2002; 277(4): 2377 - 2380. [Abstract] [Full Text] [PDF] |
||||








